Established breast cancer risk factors by clinically important tumour characteristics

M García-Closas, L A Brinton, J Lissowska, N Chatterjee, B Peplonska, W F Anderson, N Szeszenia-Dabrowska, A Bardin-Mikolajczak, W Zatonski, A Blair, Z Kalaylioglu, G Rymkiewicz, D Mazepa-Sikora, R Kordek, S Lukaszek, M E Sherman, M García-Closas, L A Brinton, J Lissowska, N Chatterjee, B Peplonska, W F Anderson, N Szeszenia-Dabrowska, A Bardin-Mikolajczak, W Zatonski, A Blair, Z Kalaylioglu, G Rymkiewicz, D Mazepa-Sikora, R Kordek, S Lukaszek, M E Sherman

Abstract

Breast cancer is a morphologically and clinically heterogeneous disease; however, it is less clear how risk factors relate to tumour features. We evaluated risk factors by tumour characteristics (histopathologic type, grade, size, and nodal status) in a population-based case-control of 2386 breast cancers and 2502 controls in Poland. Use of a novel extension of the polytomous logistic regression permitted simultaneous modelling of multiple tumour characteristics. Late age at first full-term birth was associated with increased risk of large (> 2 cm) tumours (odds ratios (95% confidence intervals) 1.19 (1.07-1.33) for a 5-year increase in age), but not smaller tumours (P for heterogeneity adjusting for other tumour features (Phet) = 0.007). On the other hand, multiparity was associated with reduced risk for small tumours (0.76 (0.68-0.86) per additional birth; Phet = 0.004). Consideration of all tumour characteristics simultaneously revealed that current or recent use of combined hormone replacement therapy was associated with risk of small (2.29 (1.66-3.15)) and grade 1 (3.36 (2.22-5.08)) tumours (Phet = 0.05 for size and 0.0008 for grade 1 vs 3), rather than specific histopathologic types (Phet = 0.63 for ductal vs lobular). Finally, elevated body mass index was associated with larger tumour size among both pre- and postmenopausal women (Phet = 0.05 and 0.0001, respectively). None of these relationships were explained by hormone receptor status of the tumours. In conclusion, these data support distinctive risk factor relationships by tumour characteristics of prognostic relevance. These findings might be useful in developing targeted prevention efforts.

Figures

Figure 1
Figure 1
Predictors of invasive breast cancer risk in the Polish Breast Cancer Study by histological subtypes. Odds ratios (95% CI) for ductal carcinomas, NOS (N=1,251) are shown in black, for lobular carcinomas (N=342) in blue, for tubular carcinomas (N=119) in red, and for mixed carcinoma (N=252) in green. Numbers in brackets denote statistically significant heterogeneity of ORs for lobular, tubular, and mixed compared to ductal carcinomas, NOS, respectively, based on standard polytomous logistic regression among cases: (1) 0.13, 0.002, and 0.98. Analyses are adjusted for age, study site, menopausal status, education level, family history, prior benign breast biopsy, screening mammogram, and all other factors shown in the figure. Comparison groups are 5-year increases for ages at menarche, first full-term birth, and menopause; each additional birth for number of full-term births; never HRT users for current or recent use of combined HRT; 5 unit increases for BMI.
Figure 2
Figure 2
Predictors of invasive breast cancer (ductal carcinomas, NOS, tubular, lobular, and mixed types) in the Polish Breast Cancer Study by tumour grade, size, and nodal status. Odds ratio (95% CI) for grade 1 (N=333), small (⩽2 cm, N=988), or node negative (N=1084) tumours are shown in black; for grade 2 (N=979), large (>2 cm, N=796), or node positive (N=708) are shown in blue; and for grade 3 (N=500) are shown in red. Numbers in brackets denote statistically significant heterogeneity of ORs based on standard polytomous logistic regression among cases: (1) 0.001 and 0.00008 for grades 2 and 3 compared to grade 1 tumours, respectively; (2) 0.02, (3) 0.0019, (4) 0.001, (5) 0.0006, and (6) 0.0005 for small (⩽2 cm) compared to large (>2 cm) tumours; and (7) 0.02, (8) 0.006, (9) 0.002, and (10) 0.02 for node positive compared to node negative tumours. Analyses are adjusted for age, study site, menopausal status, education level, family history, prior benign breast biopsy, screening mammogram, and all other factors shown in the figure. Comparison groups are 5-year increases for ages at menarche, first full-term birth, menopause; each additional birth for number of full-term births; never HRT users for current or recent use of combined HRT; 5 unit increases for BMI.

References

    1. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13: 1558–1568
    1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76: 27–36
    1. Anderson WF, Chu KC, Chang S, Sherman ME (2004a) Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 13: 1128–1135
    1. Anderson WF, Chu KC, Devesa SS (2004b) Distinct incidence patterns among in situ and invasive breast carcinomas,with possible etiologic implications. Breast Cancer Res Treat 88: 149–159
    1. Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90: 127–137
    1. Chatterjee N (2004) A two-stage regression model for epidemiological studies with multivariate disease classification data. JASA 99: 127–138
    1. Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287: 734–741
    1. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047–1059
    1. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL (2002) Body mass and stage of breast cancer at diagnosis. Int J Cancer 98: 279–283
    1. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95: 2455–2464
    1. Daniell HW (1988) Increased lymph node metastases at mastectomy for breast cancer associated with host obesity, cigarette smoking, age, and large tumor size. Cancer 62: 429–435
    1. Donegan WL, Hartz AJ, Rimm AA (1978) The association of body weight with recurrent cancer of the breast. Cancer 41: 1590–1594
    1. Elston CW, Ellis IO (1998) Assessment of histological grade. In The Breast, Elston CW, Ellis IO (eds) pp 356–384. Edinburgh, New York: Churchill Livingstone
    1. Eusebi V, Betts CM, Bussolati G (1979) Tubular carcinoma: a variant of secretory breast carcinoma. Histopathology 3: 407–419
    1. Ewertz M, Duffy SW (1988) Risk of breast cancer in relation to reproductive factors in Denmark. Br J Cancer 58: 99–104
    1. Fisher ER, Gregorio RM, Redmond C, Fisher B (1977) Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol 8: 679–683
    1. Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281: 2091–2097
    1. Green I, McCormick B, Cranor M, Rosen PP (1997) A comparative study of pure tubular and tubulolobular carcinoma of the breast. Am J Surg Pathol 21: 653–657
    1. Hall HI, Coates RJ, Uhler RJ, Brinton LA, Gammon MD, Brogan D, Potischman N, Malone KE, Swanson CA (1999) Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer 82: 23–27
    1. Hellman S, Harris JR (2000) Natural history of breast cancer. In Disease of the Breast, Harris JP, Lippman ME, Morrow M, Osborne CK (eds) pp 407–423. Philadelphia: Lippincott Williamns & Wilkins
    1. Howson CP, Kinne D, Wynder EL (1986) Body weight, serum cholesterol, and stage of primary breast cancer. Cancer 58: 2372–2381
    1. Ingram D, Nottage E, Ng S, Sparrow L, Roberts A, Willcox D (1989) Obesity and breast disease. The role of the female sex hormones. Cancer 64: 1049–1053
    1. Jones BA, Kasi SV, Curnen MG, Owens PH, Dubrow R (1997) Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 146: 394–404
    1. Lacroix M, Toillon RA, Leclercq G (2004) Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11: 497–522
    1. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289: 3254–3263
    1. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93: 1046–1052
    1. Li CI, Weiss NS, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88: 2570–2577
    1. LiVolsi VA, Kelsey JL, Fischer DB, Holford TR, Mostow ED, Goldenberg IS (1982) Effect of age at first childbirth on risk of developing specific histologic subtype of breast cancer. Cancer 49: 1937–1940
    1. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L (2001) Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 92: 919–922
    1. Morrison AS (1976) Histologic specificity of the effect of age at birth of first child on breast cancer risk. Int J Cancer 18: 723–726
    1. Mueller CB (1988) Stage II breast cancer is not simply a late stage I. Surgery 104: 631–638
    1. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11: 593–600
    1. Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA, Daling JR (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14: 225–233
    1. Reeves MJ, Newcomb PA, Remington PL, Marcus PM, MacKenzie WR (1996) Body mass and breast cancer. Relationship between method of detection and stage of disease. Cancer 77: 301–307
    1. Stalsberg H, Thomas DB, Noonan EA (1989) Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 44: 399–409
    1. Verreault R, Brisson J, Deschenes L, Naud F (1989) Body weight and prognostic indicators in breast cancer. Modifying effect of estrogen receptors. Am J Epidemiol 129: 260–268
    1. Wohlfahrt J, Andersen PK, Mouridsen HT, Adami HO, Melbye M (1999) Reproductive history and stage of breast cancer. Am J Epidemiol 150: 1325–1330
    1. Yasui Y, Potter JD (1999) The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10: 431–437

Source: PubMed

3
구독하다